Windtree Completes Enrollment Of Phase 2b Study Of Istaroxime In Early Cardiogenic Shock Caused By Heart Failure
Windtree Completes Enrollment Of Phase 2b Study Of Istaroxime In Early Cardiogenic Shock Caused By Heart Failure
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has successfully completed enrollment in its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure. The study is evaluating the ability of istaroxime to improve heart function and low blood pressure in the setting of early cardiogenic shock due to heart failure. The Company is looking to extend the positive results on these parameters as observed in the Company's first SEISMiC Phase 2 clinical study that was previously reported. In addition, the Company hopes that the study results will substantiate the encouraging observations from the Company's Phase 2 clinical study, indicating istaroxime has a favorable renal profile and does not increase cardiac arrhythmias. The SEISMiC Extension Study is utilizing longer dosing duration and tapering the dosing to assess the potential benefits.
專注於推進危重症狀和疾病早期和晚期創新療法的生物技術公司Windtree Therapeutics, Inc.（「Windtree」 或 「公司」）（納斯達克股票代碼：WINT）今天宣佈，它已成功完成其地震擴展20期研究的註冊，該研究是針對心力衰竭引起的早期心源性休克。該研究正在評估在心力衰竭導致的早期心源性休克背景下，依司他辛改善心臟功能和降低血壓的能力。該公司希望擴大在這些參數上取得的積極結果，正如該公司先前報告的首份地震二期臨床研究所觀察到的那樣。此外，該公司希望研究結果將證實該公司2期臨床研究中令人鼓舞的觀察結果，表明伊司他辛具有良好的腎臟特徵，不會增加心律失常。地震擴展研究利用更長的給藥時間，並逐漸縮減劑量，以評估潛在的益處。
